Please sign in to follow a disease.
Can an ultrasound predict who can skip surgery for rectal cancer?
NCT ID NCT03068403
First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 2 times
Summary
This study tested whether a special ultrasound technique (D-CEUS) can predict how well rectal cancer responds to chemotherapy and radiation. The goal is to identify good responders who might avoid major surgery and instead have a less invasive procedure. Only 2 people took part, making this a very early exploration.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Dynamic contrast-enhanced ultrasound (D-CEUS) with Sonovue contrast agent
- What this could lead to
- If successful, this imaging method could help identify rectal cancer patients who respond well to chemoradiation, allowing them to avoid major surgery.
- What could go wrong
- This was a very small early study with only 2 participants, so results may not apply to larger groups. The technique is still experimental and needs much more testing.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
2 people
The number who actually took part.
- Started
-
Jun 2018
- Finished
-
Jan 2019
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Histologically confirmed rectal carcinoma * Stade ≥T2 and tumor size ≥3cm * No detectable metastases * Patient ≥ 18 years * Patient information and written informed consent form signed * Patient who can receive radiotherapy and chemotherapy * Negative pregnancy test in women of childbearing potential * Patient covered by a Social Security system Exclusion Criteria: * Indication for immediate surgery * Primary tumor not measured at the MRI before inclusion * Previous pelvic radiotherapy * Contraindication to SONOVUE or MRI
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Rectal cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU de Bordeaux
Bordeaux, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Robotic surgery vs standard approaches: does the platform change cancer outcomes?
- Can two immunotherapy drugs help rectal cancer patients skip pelvic radiation?
- Can digital surveys capture the full toll of rectal cancer treatment?
- Can a targeted drug conjugate outsmart advanced colorectal cancer?
- Can a platform trial match the right drug combo to each tumor?
- Laser light may help surgeons spot risky bowel connections